Literature DB >> 22901097

A MiniReview of the use of hospital-based databases in observational inpatient studies of drugs.

Michael D Larsen1, Thomas Cars, Jesper Hallas.   

Abstract

The majority of pharmacoepidemiological data resources are based on data generated in primary health care. Although inpatient data resources have existed since the 1960s, inpatient pharmacoepidemiological studies are relatively scarce. The objectives of this MiniReview were to describe pharmacoepidemiological studies in hospital settings and the underlying databases to provide an overview of research questions addressed by such databases. The studies were retrieved by chain searching. We included pharmacoepidemiological studies in hospital settings containing data on inpatient drug use. Twelve inpatient databases in Asia, the United States and Europe were found. Most databases were automatically collected from claims data or generated from electronic medical records. The contents of the databases varied as well as the potential for linkage with other data sources such as laboratory and outpatient data. Twenty studies were selected and discussed to illustrate the diversity of inpatient pharmacoepidemiological studies. Hospital-based databases had mainly been used for drug utilization studies and research in adverse drug reactions. Five studies within comparative effectiveness were found. The number of pharmacoepidemiological studies in inpatient settings was low compared with studies from primary healthcare settings. These resources may be under-utilized.
© 2012 The Authors Basic & Clinical Pharmacology & Toxicology © 2012 Nordic Pharmacological Society.

Entities:  

Mesh:

Year:  2012        PMID: 22901097     DOI: 10.1111/j.1742-7843.2012.00928.x

Source DB:  PubMed          Journal:  Basic Clin Pharmacol Toxicol        ISSN: 1742-7835            Impact factor:   4.080


  7 in total

1.  Sources of European drug consumption data at a country level.

Authors:  Pili Ferrer; Elena Ballarín; Mònica Sabaté; Joan-Ramon Laporte; Marieke Schoonen; Marietta Rottenkolber; Joan Fortuny; Joerg Hasford; Iain Tatt; Luisa Ibáñez
Journal:  Int J Public Health       Date:  2014-05-30       Impact factor: 3.380

2.  The influence of comprehensive geriatric assessment on drug therapy in elderly patients.

Authors:  Michael Due Larsen; Jens Ulrik Rosholm; Jesper Hallas
Journal:  Eur J Clin Pharmacol       Date:  2013-11-06       Impact factor: 2.953

3.  Safety, Utilization, and Cost of Image-Guided Percutaneous Liver Biopsy Among Cancer Patients.

Authors:  Zhu Cui; Jason D Wright; Melissa K Accordino; Donna Buono; Alfred I Neugut; Jim C Hu; Dawn L Hershman
Journal:  Cancer Invest       Date:  2016-04-11       Impact factor: 2.176

4.  Temporal trends of esophageal disorders by age in the Cerner Health Facts database.

Authors:  Jessica L Petrick; Tuyet Nguyen; Michael B Cook
Journal:  Ann Epidemiol       Date:  2015-12-11       Impact factor: 3.797

5.  The intriguing future of pharmacoepidemiology.

Authors:  Björn Wettermark
Journal:  Eur J Clin Pharmacol       Date:  2013-05-03       Impact factor: 2.953

6.  The Danish National Prescription Registry in studies of a biological pharmaceutical: palivizumab - validation against two external data sources.

Authors:  Ann Haerskjold; Lonny Henriksen; Susanne Way; Mikkel Malham; Jesper Hallas; Lars Pedersen; Lone Graff Stensballe
Journal:  Clin Epidemiol       Date:  2015-05-08       Impact factor: 4.790

7.  A framework for monitoring of new drugs in Sweden.

Authors:  Thomas Cars; Lars Lindhagen; Johan Sundström
Journal:  Ups J Med Sci       Date:  2019-01-28       Impact factor: 2.384

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.